OmniAb
OABI
About: OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
Employees: 114
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
100% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 2 (+1) [Q2]
81% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 31
5% less funds holding
Funds holding: 151 [Q1] → 144 (-7) [Q2]
6.91% less ownership
Funds ownership: 51.88% [Q1] → 44.97% (-6.91%) [Q2]
22% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 32
37% less capital invested
Capital invested by funds: $152M [Q1] → $95.5M (-$56.4M) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
|
RBC Capital
Conor McNamara
|
$3
|
Outperform
Maintained
|
7 Aug 2025 |
Financial journalist opinion
Based on 3 articles about OABI published over the past 30 days
